Shire ADHD drug gets new FDA approval

Posted: July 06, 2010

Shire P.L.C. has received FDA approval for its ADHD treatment Daytrana to be used for teens age 13 to 17.

The medication, which is administered by transdermal patch, had been approved previously by the U.S. Food and Drug Administration for patients age 6 to 12. It is a treatment designed to be used in conjunction with psychological, educational and other measures.

Shire, which is based in Dublin, Ireland, has headquarters in Basingstoke, England, and operations in Chester County. - Roslyn Rudolph

comments powered by Disqus
|
|
|
|
|